6 results match your criteria: "The Geisel School of Medicine at Dartmouth and The Dartmouth-Hitchcock Medical Center[Affiliation]"
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
J Clin Oncol
June 2023
UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
Article Synopsis
- The study investigated whether adding abiraterone acetate and prednisone (AAP) to enzalutamide could improve overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC).
- A total of 1,311 patients were randomly assigned to receive either enzalutamide alone or enzalutamide plus AAP, finding no significant difference in OS between the two groups, but a longer radiographic progression-free survival (rPFS) for those receiving the combination.
- The results suggest that while AAP enhanced rPFS, it did not significantly extend OS, possibly due to increased clearance of abiraterone when combined with enzalutamide, which might have limited its effectiveness.
Post-remission strategies after dasatinib-corticosteroid induction in adult Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) are not well studied. We evaluated dasatinib and dexamethasone induction then protocol-defined post-remission therapies, including hematopoietic cell transplantation (HCT). Adults (N = 65) with Ph-positive ALL received dasatinib-dexamethasone induction, methotrexate-based central nervous system (CNS) prophylaxis, reduced-intensity conditioning (RIC) allogeneic HCT, autologous HCT, or chemotherapy alone, and dasatinib-based maintenance.
View Article and Find Full Text PDFMedicamenta ad sentinam, et defectum vitae: Drugs and failure of the pump of life-cardiotoxicity of oncotherapeutics.
Br J Clin Pharmacol
March 2021
Section of Clinical Pharmacology, Department of Medicine, The Geisel School of Medicine at Dartmouth and The Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
A Study of the Pharmacokinetic Properties and the In Vivo Kinetics of Erythrocytes Loaded With Dexamethasone Sodium Phosphate in Healthy Volunteers.
Transfus Med Rev
April 2018
Department of Pathology, The Geisel School of Medicine at Dartmouth and The Dartmouth-Hitchcock Medical Center, Lebanon, NH. Electronic address:
The objectives of this 2-phase study were to elucidate pharmacokinetics (PK), in vivo 24-hour recovery, and red blood cell (RBC) survival properties of RBC-encapsulated dexamethasone sodium phosphate (DSP) prepared using the EryDex System (EDS). The 24-hour RBC recovery and T50 survival phase studied subjects were randomized to receive autologous RBCs loaded with either 15-20 mg DSP (Group 1A) or sham saline (Group 2A). Loaded RBCs were radiolabeled with 51-Cr, and the labeled RBCs were followed over time in vivo.
View Article and Find Full Text PDFS-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.
Ther Drug Monit
June 2016
*Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego (UCSD), La Jolla; †Bertino Consulting, Schenectady, New York; ‡Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; §Disposition Safety and Animal Research, Sanofi, Bridgewater, New Jersey; and ¶Section of Clinical Pharmacology, Deptartment of Medicine, The Geisel School of Medicine at Dartmouth and The Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Background: Phenotyping cytochrome P450 (CYP) 2C9 activity using S-warfarin has routinely required extensive blood sampling over at least 96 hours after dose to estimate the area under the concentration time curve from zero to infinity (AUC). Alternatively, S-warfarin limited sampling models (LSMs) using one or 2 concentration timepoints have been proposed to estimate AUC. This study evaluated whether S-warfarin LSMs accurately estimate CYP2C9 baseline and induction conditions in healthy adults and in advanced-stage cancer patients.
View Article and Find Full Text PDFTreatment of Chronic Constipation: Prescription Medications and Surgical Therapies.
Gastroenterol Hepatol (N Y)
February 2015
Dr Hussain is a gastroenterology fellow, Ms Everhart is a medical student, and Dr Lacy is a professor of medicine and chief of the Section of Gastroenterology and Hepatology at the Geisel School of Medicine at Dartmouth and the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire.
Constipation is a highly prevalent disorder that affects people regardless of age, race, gender, or socioeconomic status. For many patients, constipation is a chronic condition that reduces quality of life. Chronic constipation also imposes a significant economic burden on the health care system.
View Article and Find Full Text PDF